Immunocore Holdings PLC (IMCR) News

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral...

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities